As the fourth and final segment, this conversation brings the series full circle. After framing obesity’s heterogeneity, exploring amylin biology, and considering phenotype-guided care, it turns to the closing question: as these therapies arrive, how do we evaluate them — and whom might they help? A forward-looking, evidence-grounded finish for clinicians preparing for what comes next. All data discussed are investigational and presented as such.
- Activities▼
- Education Hubs▼
-
- Alzheimer’s Disease
- Cardiology
- COVID-19
- Dermatology
- Gastroenterology
- Health Access & Social Responsibility
- Hematology
- Immunodeficiency Disorders
- Infectious Disease
- Liver Disease
- Metabolic Diseases Education
- Migraine
- Multiple Sclerosis
- Neuropsychiatric
- Oncology
- Ophthalmology
- Pain Management
- Pediatrics
- Pharmacist Central
- Psoriatic Arthritis
- Rare Diseases
- Respiratory
- Rheumatology
- Sleep Disorders
- Transplant
- Virtual Education
-
- Services▼
- News▼
- ▼